THE MCMANUS GROUP

Lobbying for AMGEN

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · District of Columbia · House · Senate · $60,000.00 income · posted Apr 20, 2026

Lobbying activity 1

Medicare/Medicaid

Access and reimbursement for Part B and Part D drugs. Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. Issues related to physician reimbursement under Medicare Part B drugs. Policies related to the Most Favored Nation Drug Pricing Model

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.